Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 28, 2009; 15(36): 4511-4517
Published online Sep 28, 2009. doi: 10.3748/wjg.15.4511
Published online Sep 28, 2009. doi: 10.3748/wjg.15.4511
Table 2 EGFR and HER2 expression and clinicopathological factors (Cox’s model)
| Parameter | EGFR 2+ and 3+ tumors | P | HER2 2+ and 3+ tumors | P |
| Gallbladder cancer | 5/13 | 8/34 | ||
| Mass forming type | 6/24 | 0.088 | 7/47 | 0.517 |
| Intraductal growth type | 11/19 | 10/43 | ||
| Histological type | ||||
| Well differentiated | 2/3 | 1/8 | ||
| Moderately differentiated | 16/39 | 0.511 | 20/80 | 0.202 |
| Poorly differentiated | 4/14 | 4/36 | ||
| Stage1 | ||||
| I | 3/4 | 4/9 | ||
| II | 2/6 | 0.317 | 4/20 | 0.059 |
| III | 8/17 | 9/31 | ||
| IV | 9/29 | 8/64 | ||
| Chemotherapy | ||||
| Partial response | 2/3 | 4/9 | ||
| Stable disease | 3/13 | 0.296 | 4/27 | 0.156 |
| Progressive disease | 5/13 | 5/26 |
- Citation: Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15(36): 4511-4517
- URL: https://www.wjgnet.com/1007-9327/full/v15/i36/4511.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4511